Shay Capital’s Ocular Therapeutix OCUL Stock Holding History

Shay Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-63,000	Closed	-$765K	–	598
2025 Q4	$765K	Sell	63,000 -21,500	-25%	-$261K	0.08%	220
2025 Q3	$988K	Buy	+84,500	New	+$1.01M	0.09%	173

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Shay Capital's OCUL Position: Q1 2026 in Review

Shay Capital sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 63,000 shares — an estimated $765K sold.

Shay Capital first reported a position in OCUL in Q3 2025 and held it in 2 quarters. The position peaked at $988K in Q3 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Shay Capital reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
Shay Capital sold 63,000 Ocular Therapeutix shares in Q1 2026, an estimated $765K.
Shay Capital first reported a position in Ocular Therapeutix in Q3 2025 and held it in 2 quarters.
Shay Capital's Ocular Therapeutix position peaked at $988K in Q3 2025.
271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Shay Capital's 13F filing for Q1 2026, filed 15 May 2026.